Past performance does not predict future results. Informational only, not investment advice.
SING GEORGE L (Director at REGENERON PHARMACEUTICALS, INC.) reported an open-market sale of 21,129 shares of REGN at an average $964.38, roughly $20,376,358, in a Form 4 filed 2026-11-04.
POON CHRISTINE A (Director at REGENERON PHARMACEUTICALS, INC.) reported an open-market sale of 7,830 shares of REGN at an average $969.09, roughly $7,587,958, in a Form 4 filed 2026-11-04.
LAROSA JOSEPH J (EVP General Counsel and Secret at REGENERON PHARMACEUTICALS, INC.) reported an open-market sale of 4,466 shares of REGN at an average $965.49, roughly $4,311,890, in a Form 4 filed 2026-11-04.
Regeneron represents a value opportunity in healthcare, benefiting from sector tailwinds including aging demographics and AI integration into life-saving therapeutics.
End of results.